Repeated administration of soluble peptide antigen renders antigen-specific CD4+ T cells tolerant: they become anergic, express inhibitory receptors, and activate immunosuppressive genes while losing the ability to induce immune-response genes. Bevington et al. (Cell Reports, 2020) proposed a two-step model in which inhibitory receptors weaken TCR/CD28 signaling below the threshold required for immune-response genes, while epigenetic priming at tolerance-associated DNase I hypersensitive sites (tDHSs) keeps tolerance-associated genes responsive to the weakened signal. The evidence for this model is largely correlative. This problem asks for the missing causal, mechanism-level account: the biochemical pathways from inhibitory receptors such as TIM3, LAG3, and TIGIT to repressive effectors such as the ubiquitin ligase Cbl-b; whether NFAT occupies tDHSs in resting tolerized cells; whether individual tDHSs are causally responsible for lowered activation thresholds; and the determinants distinguishing this state from other anergic/exhausted states. All four elements remain open in the literature as of 2026.

Background

Peripheral T cell tolerance prevents immune attack on the body's own tissues. One route to it is tolerization: repeated exposure to soluble peptide antigen (in mice, studied with antigen-specific transgenic T cell receptors such as the Tg4 model recognizing a myelin basic protein epitope) renders antigen-specific CD4+ T cells anergic — unable to mount inflammatory effector responses — while steering them toward an anti-inflammatory, IL-10-producing type 1 regulatory (Tr1)-like phenotype. T cell activation normally requires two signals: engagement of the T cell receptor (TCR) with peptide-MHC and co-stimulation through CD28. Downstream, TCR/CD28 signaling activates transcription factors including NFAT (nuclear factor of activated T cells, a calcium/calcineurin-responsive factor), AP-1 (induced downstream of Ras and PKC pathways), NF-κB, and IRF family members; NFAT and AP-1 normally cooperate at composite DNA motifs to induce immune-response genes such as Il2, Csf2, and Tnf. When signaling is weakened, NFAT acts without AP-1 and instead drives anergy- and tolerance-associated programs. Bevington et al. (2020) mapped the epigenetic basis of this switch. DNase I hypersensitive sites (DHSs) are markers of open, accessible regulatory chromatin (promoters and enhancers) detected by DNase-seq; a pre-existing open DHS that poises a gene for faster or stronger later induction is called a primed DHS. The authors identified 1,033 DHSs specific to resting tolerized cells (tDHSs), enriched in AP-1 and NFAT motifs and located near tolerance-associated genes such as Ctla4, Il10, Tigit, and Nrp1, and showed that tolerized cells fail to prime the DHSs characteristic of memory T cells. Inhibitory receptors (CTLA4, PD-1, and the less characterized TIM3, LAG3, TIGIT) suppress signaling: CTLA4 and PD-1 are known to activate Cbl-b, an E3 ubiquitin ligase that raises the T cell activation threshold by ubiquitinating signaling components (the p85 subunit of PI3K, PKC-θ, and PLC-γ1), and the authors showed ZAP70 and PKC-θ fail to localize at the immunological synapse in tolerized cells. On this basis the paper proposed a two-step model: (1) inhibitory receptors, via effectors such as Cbl-b, lower TCR/CD28 signaling below the threshold needed to induce immune-response genes; (2) chromatin priming at tDHSs allows tolerance-associated genes to be activated by that reduced signal. However, the support for step 2 was correlative (tDHS strength tracked gene inducibility; footprinting was performed on re-stimulated cells; NFAT binding was inferred from motif presence and public ChIP-seq of a constitutively active NFAT), and the pathways from TIM3, LAG3, and TIGIT to Cbl-b or comparable effectors were explicitly stated to remain poorly understood. Tolerized cells also differ from exhausted CD8 T cells, tumor-infiltrating lymphocytes, and in vitro Tr1 cells in suppressed NR4A-family transcription factor signaling and loss of LEF/TCF motif utilization, for reasons not determined. Whether peptide-induced tolerization can be deployed safely and durably in human autoimmune disease was, and remains, an open translational question.

Problem Statement

Provide the causal, mechanism-level account of the two-step model of CD4+ T cell tolerance proposed by Bevington et al. (2020), in which inhibitory receptors lower TCR/CD28 signaling below the threshold required for immune-response genes while chromatin priming at tolerance-associated DNase I hypersensitive sites (tDHSs) permits activation of tolerance-associated genes at that reduced signal. Concretely: (1) determine whether and how inhibitory receptors other than PD-1 and CTLA4 — notably TIM3, LAG3, and TIGIT — signal to repressive effectors such as the E3 ubiquitin ligase Cbl-b in tolerized T cells, and, if so, identify the receptor-proximal mechanisms and the downstream substrates ubiquitinated; (2) determine whether NFAT is already bound at tDHS motifs in resting tolerized cells prior to re-stimulation, or whether occupancy of these sites requires antigen re-encounter; (3) establish whether specific tDHSs are causally necessary or sufficient for the lowered activation thresholds of the tolerance-associated genes they neighbor — for example by targeted deletion or epigenetic editing of individual tDHSs followed by tolerization and quantification of gene induction across TCR/CD28 signal strengths; (4) identify the determinants and functional consequences of the state-specific differences between peptide-tolerized CD4+ T cells and other hyporesponsive states (chronic-infection exhaustion, tumor-infiltrating lymphocyte dysfunction, in vitro Tr1 cells), including the suppressed NR4A-family signaling and lost LEF/TCF motif utilization observed in tolerized cells. Elements (1)-(4) jointly validate the causal chain of the model (upstream signaling, transcription-factor access to primed chromatin, chromatin causality for threshold resetting, and state specificity of the mechanism) and constitute the mechanistic core of the model. All four elements are required for a resolution; an account addressing fewer than four does not resolve the task.

References

  1. Bevington S.L., Ng S.T.H., Britton G.J., Keane P., Wraith D.C., Cockerill P.N. Chromatin Priming Renders T Cell Tolerance-Associated Genes Sensitive to Activation below the Signaling Threshold for Immune Response Genes. Cell Reports 31(10):107748, 2020. DOI: 10.1016/j.celrep.2020.107748. https://doi.org/10.1016/j.celrep.2020.107748 (source paper)
  2. Cassano A., Abbondanza D., Chong A.S., Alegre M.-L. Cell-intrinsic CD4 T cell tolerance: a new frontier in therapy? Trends in Immunology 46(9):624-634, 2025. DOI: 10.1016/j.it.2025.07.001. https://doi.org/10.1016/j.it.2025.07.001
  3. Chocarro L., Blanco E., Fernandez-Rubio L., Garnica M., Zuazo M., Garcia M.J., Bocanegra A., Echaide M., Johnston C., Edwards C.J., Legg J., Pierce A.J., Arasanz H., Fernandez-Hinojal G., Vera R., Ausin K., Santamaria E., Fernandez-Irigoyen J., Kochan G., Escors D. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets. EMBO Molecular Medicine 16(8):1791-1816, 2024. DOI: 10.1038/s44321-024-00098-y. https://doi.org/10.1038/s44321-024-00098-y
  4. Titcombe P.J., Silva Morales M., Zhang N., Mueller D.L. BATF represses BIM to sustain tolerant T cells in the periphery. Journal of Experimental Medicine 220(12):e20230183, 2023. DOI: 10.1084/jem.20230183. https://doi.org/10.1084/jem.20230183
  5. Trefzer A., Kadam P., Wang S.-H., Pennavaria S., Lober B., Akçabozan B., Kranich J., Brocker T., Nakano N., Irmler M., Beckers J., Straub T., Obst R. Dynamic adoption of anergy by antigen-exhausted CD4+ T cells. Cell Reports 34(6):108748, 2021. DOI: 10.1016/j.celrep.2021.108748. https://doi.org/10.1016/j.celrep.2021.108748
  6. Hong S.W., Krueger P.D., Osum K.C., Dileepan T., Herman A., Mueller D.L., Jenkins M.K. Immune tolerance of food is mediated by layers of CD4+ T cell dysfunction. Nature 607(7920):762-768, 2022. DOI: 10.1038/s41586-022-04916-6. https://doi.org/10.1038/s41586-022-04916-6
  7. Elliot T.A.E., Jennings E.K., Lecky D.A.J., Thawait N., Flores-Langarica A., Copland A., Maslowski K.M., Wraith D.C., Bending D. Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength. Immunity 54(11):2481-2496.e6, 2021. DOI: 10.1016/j.immuni.2021.08.020. https://doi.org/10.1016/j.immuni.2021.08.020
  8. Cepika A.M., Amaya L., Waichler C., Narula M., Mantilla M., Thomas B.C., Chen P.P., Freeborn R.A., Pavel-Dinu M., Nideffer J., Porteus M., Bacchetta R., Müller F., Greenleaf W.J., Chang H.Y., Roncarolo M.G. Epigenetic landscape, key transcriptional regulators, and in vivo identification of human Tr1 cells. Science Advances 12(28):eaec6358, 2026. DOI: 10.1126/sciadv.aec6358. https://doi.org/10.1126/sciadv.aec6358
  9. Kenison J.E., Stevens N.A., Quintana F.J. Therapeutic induction of antigen-specific immune tolerance. Nature Reviews Immunology 24(5):338-357, 2024. DOI: 10.1038/s41577-023-00970-x. https://doi.org/10.1038/s41577-023-00970-x
  10. Wraith D.C. Antigen-specific immunotherapy of multiple sclerosis and other autoimmune diseases. Seminars in Arthritis and Rheumatism 72S:152682, 2025. DOI: 10.1016/j.semarthrit.2025.152682. https://doi.org/10.1016/j.semarthrit.2025.152682
  11. Kressler C., Gasparoni G., Nordström K., Hamo D., Salhab A., Dimitropoulos C., Tierling S., Reinke P., Volk H.-D., Walter J., Hamann A., Polansky J.K. Targeted De-Methylation of the FOXP3-TSDR Is Sufficient to Induce Physiological FOXP3 Expression but Not a Functional Treg Phenotype. Frontiers in Immunology 11:609891, 2021. DOI: 10.3389/fimmu.2020.609891. https://doi.org/10.3389/fimmu.2020.609891